fenfluramine
E874310
Fenfluramine is a medication repurposed from its former use as an appetite suppressant to serve as an anti-seizure drug, particularly effective in reducing seizures in patients with Dravet syndrome.
All labels observed (1)
| Label | Occurrences |
|---|---|
| fenfluramine canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10609983 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: fenfluramine Context triple: [Dravet syndrome, hasTreatment, fenfluramine]
-
A.
Fenodyree
Fenodyree is a mythical, goblin-like creature from Alan Garner’s fantasy novel "The Weirdstone of Brisingamen," known for aiding the protagonists with its otherworldly powers and knowledge of the hidden realms.
-
B.
terfenadine
Terfenadine is a withdrawn second-generation antihistamine formerly used to treat allergy symptoms but discontinued due to its risk of causing serious cardiac arrhythmias.
-
C.
Lamotrek
Lamotrek is a small atoll in the Federated States of Micronesia known for its traditional seafaring culture and navigational expertise.
-
D.
Ripatransone
Ripatransone is a historic hilltop town in Italy’s Marche region, known for its medieval architecture, panoramic views, and well-preserved old center.
-
E.
Andexxa
Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: fenfluramine Target entity description: Fenfluramine is a medication repurposed from its former use as an appetite suppressant to serve as an anti-seizure drug, particularly effective in reducing seizures in patients with Dravet syndrome.
-
A.
Fenodyree
Fenodyree is a mythical, goblin-like creature from Alan Garner’s fantasy novel "The Weirdstone of Brisingamen," known for aiding the protagonists with its otherworldly powers and knowledge of the hidden realms.
-
B.
terfenadine
Terfenadine is a withdrawn second-generation antihistamine formerly used to treat allergy symptoms but discontinued due to its risk of causing serious cardiac arrhythmias.
-
C.
Lamotrek
Lamotrek is a small atoll in the Federated States of Micronesia known for its traditional seafaring culture and navigational expertise.
-
D.
Ripatransone
Ripatransone is a historic hilltop town in Italy’s Marche region, known for its medieval architecture, panoramic views, and well-preserved old center.
-
E.
Andexxa
Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anorectic agent
ⓘ
antiepileptic drug ⓘ fluoroamphetamine derivative ⓘ medication ⓘ serotonergic agent ⓘ |
| hasAdverseEffect |
decreased appetite
ⓘ
diarrhea ⓘ fatigue ⓘ pulmonary arterial hypertension ⓘ somnolence ⓘ valvular heart disease ⓘ |
| hasATCCode |
A08AA01
ⓘ
N03AX29 ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasBrandName | Fintepla NERFINISHED ⓘ |
| hasCASNumber | 458-24-2 ⓘ |
| hasChemicalFormula | C12H16F3N ⓘ |
| hasContraindication |
concomitant use with monoamine oxidase inhibitors
ⓘ
history of valvular heart disease ⓘ pulmonary arterial hypertension ⓘ |
| hasCurrentMarketingAuthorizationHolder | UCB Pharma NERFINISHED ⓘ |
| hasDeveloper | Zogenix NERFINISHED ⓘ |
| hasDrugInteraction |
MAO inhibitors
NERFINISHED
ⓘ
SSRIs NERFINISHED ⓘ serotonergic drugs ⓘ triptans ⓘ |
| hasFormerIndication | obesity ⓘ |
| hasHalfLife | approximately 20 hours ⓘ |
| hasIUPACName | N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction |
positive modulator of sigma-1 receptor
ⓘ
serotonin releasing agent ⓘ serotonin reuptake inhibitor ⓘ |
| hasMetabolite | norfenfluramine ⓘ |
| hasMolarMass | 231.26 g/mol ⓘ |
| hasRegulatoryApprovalFor |
treatment of Dravet syndrome in children
ⓘ
treatment of Lennox–Gastaut syndrome in patients aged 2 years and older ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasStereochemistry | racemic mixture ⓘ |
| hasTherapeuticUse |
treatment of Dravet syndrome
ⓘ
treatment of Lennox–Gastaut syndrome ⓘ treatment of seizures ⓘ |
| isAdministeredAs | oral solution ⓘ |
| isExcretedBy | kidney ⓘ |
| isMetabolizedBy | liver ⓘ |
| mayCause | serotonin syndrome ⓘ |
| requiresMonitoring | echocardiogram ⓘ |
| wasRepurposedFrom | appetite suppressant ⓘ |
| wasWithdrawnAsAppetiteSuppressant | due to risk of cardiac valvulopathy ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: fenfluramine Description of subject: Fenfluramine is a medication repurposed from its former use as an appetite suppressant to serve as an anti-seizure drug, particularly effective in reducing seizures in patients with Dravet syndrome.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.